Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive Oncology, Rare/Orphan Diseases and Gene Therapy SINGAPORE, April 15, 2021 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive. Juniper Biologics will be focused on researching, developing and commercialising innovative medications in the areas of Oncology, Rare/Orphan Diseases and Gene Therapy. The company is headquartered in Singapore. Juniper Biologics was founded on a vision to provide the next generation of life-changing treatments for unmet needs focused on specialist therapy areas in which it can make the most difference. The company has the goal of bringing in cutting edge innovation and improving the quality of life of the human race and especially in the wake of the COVID-19 pandemic. Mr Singh's plan is to do this by focusing exclusively on much neglected therapy areas, specific biological targets and unique formulations with strong value proposition.